CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Trastuzumab Combination and Monotherapy for HER2 Advanced or Recurrent Uterine or Endometrial Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Last updated: November 26, 2020
Project Number: RC1319-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of trastuzumab combination therapy or trastuzumab monotherapy for human epidermal growth factor receptor 2 positive advanced or recurrent uterine or endometrial cancer?
  2. What is the cost-effectiveness of trastuzumab combination therapy or trastuzumab monotherapy for human epidermal growth factor receptor 2 positive advanced or recurrent uterine or endometrial cancer?

Key Message

One moderate quality randomized controlled trial (two publications) regarding the clinical effectiveness of trastuzumab combined with carboplatin and paclitaxel compared with carboplatin and paclitaxel alone in patients with HER2 positive uterine serous carcinoma was identified. The trial showed that trastuzumab combined with carboplatin and paclitaxel significantly improved progression-free survival and improved overall survival in patients with advanced and recurrent HER2 positive uterine serous carcinoma compared with carboplatin and paclitaxel alone. High-grade adverse events during and following treatment were not significantly different between the treatment groups. Objective response rate did not differ between groups. No clinical evidence regarding trastuzumab monotherapy or other types of trastuzumab combination therapies (e.g., trastuzumab in combination with cisplatin and paclitaxel or docetaxel), patients with non-serous uterine cancer, other comparators (e.g., docetaxel), or data on quality of life were identified. No studies were identified regarding the cost-effectiveness of trastuzumab.